Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lymphoma × Vemurafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 35 Neoplasms 14 Neoplasm Metastasis 5 Thyroid Neoplasms 3 Skin Neoplasms 2 Recurrence 2 Colorectal Neoplasms 2 Wilms Tumor 1 Urinary Bladder Neoplasms 1 Thyroid cancer, follicular 1 Thyroid Cancer, Papillary 1 Skin Diseases 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Osteosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Neoplasms, Unknown Primary 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Leukemia, Hairy Cell 1 Histiocytosis, Langerhans-Cell 1 Heterotaxy Syndrome 1 Hepatoblastoma 1 Glioma 1 Ependymoma 1 Colorectal Cancer Metastatic 1 Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 256 Rituximab 234 Etoposide 145 Filgrastim 138 Vincristine 131 Doxorubicin 124 Prednisone 105 Radiotherapy 96 Cytarabine 96 Methotrexate 77 Peripheral Blood Stem Cell Transplantation 76 fludarabine phosphate 74 Melphalan 72 Busulfan 63 Dexamethasone 57 Granulocyte Colony-Stimulating Factor 49 Carmustine 47 fludarabine 46 Bortezomib 37 Ifosfamide 36 Whole-Body Irradiation 35 Tacrolimus 35 Gemcitabine 35 Leucovorin 34 Mycophenolic Acid 33 Antilymphocyte Serum 33 Cyclosporine 29 Methylprednisolone 28 Bendamustine Hydrochloride 28 sargramostim 27

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01636622 2020-06-18

Study of Vemurafenib, Carboplatin, and Paclitaxel

M.D. Anderson Cancer Center

Phase 1 Completed

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡